Market Intelligence, Clinical Progress, and High-Purity Reagents for Heart Failure and Cardiomyopathy Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PLN drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PLN Recombinant Protein (Wild-Type & Mutants) High purity (>95%), Endotoxin controlled. Sequence Verified. Ideal for biophysical interaction assays. |
View PLN Products |
| Gene Delivery | PLN Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Essential for preserving native sarcoplasmic reticulum membrane conformation. |
View PLN Products |
| Benchmark Ab | Anti-PLN Recombinant Antibody Sequence-verified positive control for expression validation and co-localization studies. |
View PLN Products |
| Validator | PLN siRNA Set For knockdown verification in primary cardiomyocytes and hiPSC-CMs. |
View PLN Products |
| Related Target A | ATP2A2 (SERCA2a) The direct functional partner of PLN. Essential for reconstituting the calcium-uptake regulation complex. |
View ATP2A2 Products |
| Related Target B | PRKACA (PKA Catalytic Subunit) Primary kinase responsible for PLN Ser16 phosphorylation, relieving SERCA2a inhibition. |
View PRKACA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Membrane Conformation Preservation | Lentivirus Premade Particles for stable cell line construction to ensure native pentameric assembly. |
| Mutant-Specific Screening (e.g., R14del) | Sequence-verified mutant recombinant proteins and customized lentivirus vectors. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives in Knockdown | Validated siRNA included for specificity checks |
Live PLN R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PLN therapeutics is intensifying, with major players shifting focus from traditional small molecules to gene therapies and genetic medicines. As first-generation therapies reach the clinic, the next wave of R&D is targeting genetic mutations such as the PLN R14del founder mutation, which leads to severe, refractory dilated cardiomyopathy. Modulating the PLN-SERCA2a interaction remains one of the most promising avenues for restoring calcium homeostasis in chronic heart failure.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (AAV) | AskBio, Tenaya Therapeutics | Congestive Heart Failure, PLN R14del Cardiomyopathy | Transgene expression and functional rescue assays (Need PLN Lentivirus for stable cell lines) |
| Antisense Oligonucleotides (ASO) | Ionis Pharmaceuticals | Dilated Cardiomyopathy (DCM) | Target knockdown validation (Need sequence-verified PLN siRNA and qPCR controls) |
| Small Molecules / Peptides | Windtree Therapeutics, Small Molecule Startups | Acute Decompensated Heart Failure (ADHF) | Disruption of PLN-SERCA2a binding (Need high-purity recombinant PLN & ATP2A2 proteins) |